Tea catechins exhibit a broad range of pharmacological activities that impart beneficial effects on human health.
Epigallocatechin-3-gallate (EGCG), one of the major tea catechins, has been widely associated with cancer prevention and treatment. In
addition, tea catechins in combination with anticancer drugs are being evaluated as a new cancer treatment strategy. However, the
interactions of anticancer drugs with tea catechins are largely unknown. Accumulated data indicate significant interactions between
anticancer drugs and tea catechins, such as synergistic tumor inhibition or antagonist activity. Therefore, it is critical to understand
comprehensively the effects of tea catechins on anticancer drugs. Focusing on evidence from preclinical studies, this paper will review
the interactions between anticancer drugs and tea catechins, including pharmacodynamics and pharmacokinetics effects. We hope that by
detailing the interactions between anticancer drugs and tea catechins, more attention will be directed to this important therapeutic
combination in the future.